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Abstract
Introduction Using oligonucleotide microarray, many IFN-
inducible genes have been found to be highly expressed in
peripheral blood mononuclear cells (PBMCs) from most
patients with systemic lupus erythematosus (SLE). Among
these IFN-inducible genes, IFN-induced protein with
tetratricopeptide repeats 4 (IFIT4) is a novel gene whose
function is unknown.
Methods In this study we examined the role played by IFIT4 in
monocyte differentiation and the correlation between IFIT4
expression and the clinical manifestation of SLE. To this end, we
used plasmid transfection, flow cytometry, mixed leucocyte
responses, ELISA, quantitative RT-PCR and Western blotting.
Results We found that both IFIT4 mRNA and protein expression
levels were significantly higher in PBMCs and monocytes from
SLE patients than in those from healthy control individuals. IFIT4
expression was positively correlated with antinuclear antibodies,
anti-double-stranded DNA, and anti-Sm auto-immune
antibodies in SLE. Patients with SLE exhibiting higher
expression of IFIT4 had a higher prevalence of leucopenia,
thrombocytopenia and C3/C4 decrease. IFIT4 protein was
localized exclusively to the cytoplasm, and it was significantly
upregulated by IFN-α in normal PBMCs. To determine the role
played by IFIT4 in monocyte differentiation, the monocytic cell
line THP-1 was transfected with pEGFP-IFIT4 expression
plasmid and stimulated with granulocyte-macrophage colony-
stimulating factor/IL-4 to generate IFIT4-primed dendritic cell-
like cells (DCLCs). IFIT4-primed DCLCs acquired
morphological characteristics of dendritic cells more quickly,
with greater resemblance to dendritic cells, as compared with
DCLCs primed with pEGFP-C1 control plasmid trasfection.
Furthermore, they exhibited higher expressions of CD40, CD86,
CD80, HLA-DR and CD83, along with lower expression of
CD14; increased IL-12 secretion; and an increased ability to
stimulate T-cell proliferation. In addition, IFIT4-primed DCLCs
enhanced IFN-γ secretion (about 2.4-fold) by T cells compared
with controls.
Conclusion Our findings suggest that IFIT4 might play roles in
promoting monocyte differentiation into DCLCs and in directing
DCLCs to modulate T-helper-1 cell differentiation; these actions
might contribute to the autoimmunity and pathogenesis of SLE.Page 1 of 12
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ANA = antinuclear antibody; anti-dsDNA = anti-double-stranded DNA antibody; DC = dendritic cell; DCLC = dendritic cell-like cell; ELISA = enzyme-
linked immunosorbent assay; FACS = fluorescence-activated cell sorting; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; GM-CSF = gran-
ulocyte-macrophage colony-stimulating factor; IFIG = interferon-inducible gene; IFIT4 = interferon-induced protein with tetratricopeptide repeats 4; 
IFN = interferon; IL = interleukin; LPS = lipopolysaccharide; MLR = mixed leukocyte response; PBMC = peripheral blood mononuclear cell; RT-PCR 
= reverse trancription polymerase chain reaction; SLE = systemic lupus erythematosus; SLEDAI = Systemic Lupus Erythematosus Disease Activity 
Index; Th1 = T-helper-1.
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Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease with multiple organ involvement, in which autoantibod-
ies induce tissue damage. IFN-α/β [1,2] and IFN-inducible
genes (IFIGs) [3-5] are believed to play a major role in SLE.
IFN-α is a causative agent in the pathogenesis of SLE [6-8].
Elevated levels of IFN-α were detected in the sera of lupus
patients [9], and IFN-α levels in sera correlate with disease
severity and the generation of autoantibodies [10-13].
Patients treated with IFN-α occasionally develop antinuclear
antibodies (ANAs), anti-double-stranded DNA antibodies
(anti-dsDNAs) and autoimmune disorders [1,14-17] similar to
those characteristic of SLE, but the mechanism by which IFN-
α expression is associated with the generation of autoantibod-
ies in vivo requires clarification [18].
Notably, IFN-α/β was found to upregulate major histocompat-
ibility complex expression and to induce differentiation of
monocytes into dendritic cells (DCs) [19-26], antigen-pre-
senting cells that induce and regulate immune responses. An
increased number of circulating plasma cells and the presence
of autoreactive T and B cells in the sera of patients with SLE
suggest that the disease might be driven by alterations in DCs.
Moreover, Blanco and coworkers [2] reported that IFN-α in the
sera of SLE patients can induce normal monocytes to differen-
tiate into DCs. Thus, IFN-α may enhance autoimmune
responses in SLE by inducing DCs [27]. However, the mech-
anism by which IFN-α induces monocytes to differentiate into
DCs has not been elucidated.
Recently, a gene expression study using an oligonucleotide
microarray showed that many IFIGs are highly expressed in the
peripheral blood mononuclear cells (PBMCs) of most SLE
patients [3,5,28-32], and IFIGs correlated with the production
of autoantibodies and the clinical manifestations of SLE
[3,4,18,30,31]. The IFIGs were thought to be responsible for
the immunomodulatory properties of IFN, such as monocyte
differentiation and anti-proliferation. For example, Ifi204
favours macrophage differentiation in myeloid progenitor cells
[33].
Among the IFIGs, IFN-induced protein with tetratricopeptide
repeats 4 (IFIT4) is a novel gene whose function was unknown
until recently, when it was shown to be a key mediator of anti-
proliferative activity by enhancing the p21 and p27 proteins
[34,35]. Induction of IFIT4 transcription by IFN-α depends
upon the sequential activation of protein kinase Cδ, c-Jun
amino-terminal kinase, and STAT1 (signal transducer and acti-
vator of transcription 1) [36]. Because IFIT4 can be induced
by IFN-α [36], which is involved in monocyte differentiation
[2,19,20,27,37], we were interested in testing whether IFIT4
was responsible for the effect of IFN-α on differentiation of
monocytes into DCs [38].
In the present study we found that increased expression of
IFIT4 in the PBMCs of patients with SLE positively correlated
with the presence of autoantibodies (ANA, anti-dsDNA and
anti-Sm), leucocytopenia and hypocomplementaemia. Com-
pared with DC-like cells (DCLCs) primed with pEGFP-C1
transfection, IFIT4-primed DCLCs exhibited higher expression
of CD40, CD80, CD86 and HLA-DR; lower expression of
CD14; enhanced IL-12 secretion; and increased ability to
stimulate T-cell proliferation. This indicates that IFIT4 may play
a role in promoting monocyte differentiation into DCs. Moreo-
ver, IFIT4-primed DCLCs induced a differentiation bias of
CD4+ T cells into T-helper-1 (Th1) cells. These findings sug-
gest that IFIT4 might play a role in the pathogenesis of SLE by
promoting monocyte differentiation into DCs.
Materials and methods
Patients
A total of 108 patients with SLE and 46 normal healthy donors
were recruited from the Department of Rheumatology, RenJi
Hospital, which is affiliated with Shanghai Jiao Tong University
School of Medicine (Table 1). All SLE patients fulfilled the
diagnostic criteria of the American College of Rheumatology.
All of study participants signed a patient material and informed
consent form, approved by Renji Hospital Institutional Review
Board.
Samples and clinical index
Human PBMCs were isolated by Ficolle-Hypaque density gra-
dient separation. IFIT4 mRNA levels were detected by quanti-
tative RT-PCR in total RNA, isolated from the PBMCs of 108
SLE patients and 46 healthy donors with Trizol reagent. IFIT4
protein expression levels were determined by Western blot-
ting in protein samples from the PBMCs of 24 patients with
SLE and 24 healthy control individuals.
Isolation of monocytes and T cells
Blood monocytes from three patients with SLE and three
healthy control individuals were isolated using an immuno-
magnetic bead method (Miltenyi Biotec, Bergisch Gladbach,
Germany) and were used to examine the expression of IFIT4
protein via Western blotting. CD4+ lymphocytes were purified
from PBMCs via an indirect magnetic labeling system, namely
the CD4 T Cell Isolation Kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany). Purities were generally in excess of 95%.
Freshly isolated T lymphocytes were used to measure mixed
leucocyte responses (MLRs).
Quantitative real-time RT-PCR for mRNA
For quantitative analysis of gene expression, total RNA was
isolated using a Trizol reagent kit (Invitrogen, Carlsbad, CA,
USA). cDNA was synthesized and fluorescence real-time RT-
PCR was performed by using SuperScript™ III Platinum®
SYBR® Green Two-Step qRT-PCR Kits (Invitrogen, Carlsbad,
CA, USA) via the ABI PRISM 7900 system (Perkin-Elmer, Fos-
ter City, CA, USA). The following primers were used: IFIT4 for-Page 2 of 12
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reverse: 5'-GCCCTTTCATTTCTTCCACAC-3'; GAPDH for-
ward: 5'-GAAGGTGAAGGTCGGAGTC-3'; GAPDH reverse:
5'-GAAGATGGTGATGGGATTTC-3'. All data were analyzed
using ABI PRISM SDS 2.0 software (Applied Biosystems,
Foster, CA, USA). Using the ΔCt method, GAPDH was co-
amplified to normalize the amount of RNA [39].
Western blotting
Western blotting was performed as described previously
[34,39]. Protein from PBMCs and monocytes were harvested
and transferred to polyvinylidene fluoride membranes. The
membranes were incubated with monoclonal anti-human IFIT4
antibody (BD Clontech, Palo Alto, CA, USA) followed by
horseradish peroxidase-linked secondary antibodies (Cell Sig-
naling, Beverly, MA, USA). Equal protein loading for Western
blots was confirmed by immunoblotting for β-actin.
Plasmid construction and transient transfection
The cDNA fragment encoding IFIT4 was amplified by PCR
from a plasmid template (ORFEXPRESS™ Gateway® ORF
Shuttle Clones; GeneCopeia, Frederick, MD, USA), into which
the full-length human IFIT4 cDNA was inserted. PCR products
were digested by HindIII restriction endonuclease and cloned
into the pEGFP-C1 vector, generating plasmid pEGFP-IFIT4.
An endotoxin-free kit (EndoFree Plasmid isolation Kit, Qiagen,
Chatsworth, CA, USA) was used to purify the vectors. pEGFP-
C1 was used as a negative control (BD Clontech, Palo Alto,
CA, USA). For transient transfections, the plasmids mentioned
above were transfected into THP-1 cells using Lipofectamine
2000 (Invitrogen, USA) or Cell Line Nucleofector Kits V
(Amaxa Biosystems, Cologne, Germany).
Confocal microscopy
To observe the subcellular location of IFIT4, THP-1 cells were
transfected with pEGFP-IFIT4 or pEGFP-C1 empty vector.
Forty eight hours later, cells were stimulated with 3000 μ/ml
IFN-α for 3 days. The cells were examined under a confocal
microscope (Leica TCS SP2, Leica Microsystems, Heidel-
berg, Germany), using DAPI for nuclear staining.
Cell culture and generation of IFIT4-primed dendritic 
cell-like cells from THP-1 cells
The human monocytic cell line THP-1 (ATCC, Manassas, VA,
USA) [40] was cultured in RPMI 1640 (Hyclone, Logan, UT,
USA) supplemented with 10% foetal bovine serum and 2
mmol/l L-glutamine at 37°C in 5% carbon dioxide. The follow-
ing human recombinant cytokines were used as stimulators:
recombinant human granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF; 50 ng/ml), IL-4 (20 ng/ml; R&D Systems,
Minneapolis, MN, USA), and lipopolysaccharide (LPS; 100
ng/ml, Escherichia coli 0111:B:4; Sigma, St. Louis, MO,
USA).
To generate DC-like cells (DCLCs), THP-1 cells were treated
with GM-CSF and IL-4 (GM-CSF/IL-4) [40-44] at the indi-
cated concentrations for up to 6 to 12 days. To generate
IFIT4-primed DCLCs, THP-1 cells were transfected with
pEGFP-IFIT4; 36 hours later the cells were stimulated with
GM-CSF/IL-4 for up to 5 to 7 days. The DCLCs derived from
Table 1
Demographic characteristics of the study subjects
Characteristic SLE patients Healthy donors P
Participants (n) 108 46 -
Age (years) 32.52 ± 11.97 32.5 ± 14.32 0.83
Sex (n; female/male) 96/12 40/6 0.62
Onset age (years) 27.14 ± 10.0 NA -
Disease duration (years) 5.4 ± 4.13 NA -
SLEDAI-2K score (mean [range]) 6 (3 to 8) NA -
Mean ESR (mm/hour) 61.58 ± 24.03 NA -
Medical therapy (n)
Prednisone >60 mg/day 11 NA -
Prednisone 30 to 60 mg/day 44 NA -
Prednisone 0 mg/day 6 NA -
CTX 35 NA -
FIT4 relative expression 37.84 ± 3.52 10.58 ± 2.64 0.00
All patients were of Chinese ethnicity. Unless stated otherwise, values are expressed as mean ± standard deviation. CTX, cyclophosphamide; 
ESR, erythrocyte sedimentation rate; IFIT4, interferon-induced protein with tetratricopeptide repeats 4; NA, not applicable; SLE, systemic lupus 
erythematosus; SLEDAI-2K, SLE Disease Activity Index 2,000.Page 3 of 12
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Mature and active DCLCs were generated from THP-1 cells
that were treated with GM-CSF/IL-4 for 6 to 12 days and fur-
ther cultured with LPS for an additional 2 days. Cultures were
fed every 2 or 3 days by removing half of the medium and add-
ing fresh medium with full doses of cytokines.
Morphological examination
To assess the effect of IFIT4 on monocyte differentiation, the
morphology of DCLCs primed by transfection with pEGFP-C1
or pEGFP-IFIT4 was examined every day using an Olympus IX-
70 inverted microscope
Monoclonal antibodies and flow cytometry
Purified mouse IgG1, κ isotype control (Catalogue no:
400101); PE mouse IgG2b, κ isotype control, PE anti-human
CD86 (Catalogue no: 305406); CD83 (Catalogue no:
305308); HLA-DR (Catalogue no: 307606); CD1a (Cata-
logue no: 300106); and FITC anti-human CD14 (Catalogue
no: 325604) were obtained from Biolegend (San Diego, CA,
USA). FITC anti-human CD40 (Catalogue no: FAB617F) and
PE anti-human CD80 (Catalogue no: FAB140P) were from
R&D Systems, Minneapolis, MN, USA.
DCLCs were incubated with saturating concentrations of
fluorochrome-conjugated monoclonal antibodies at 4°C for 30
minutes and then washed twice in phosphate-buffered saline
containing 2% foetal bovine serum and fixed in 1% paraformal-
dehyde. Cells were analyzed with a FACSort (BD Bio-
sciences, Mountain View, CA, USA). Appropriate
fluorochrome or isotype control monoclonal antibodies of each
antibody species were used as negative controls.
Mixed leucocyte responses
Mature and active DCLCs, generated as described above,
were harvested and γ-irradiated (3,000 rads) followed by incu-
bation with 5 × 104 allogeneic CD4+ T cells/well, at ratios of
DCLCs to T cells of 1:10, 1:20 and 1:40. Three days later,
[3H]thymidine was added (0.5 μCi/well) and the cells were
incubated for another 18 hours. The cells were harvested and
the incorporated radioactivity measured using a β counter
(model LS3801; Beckman Coulter, Brea, CA, USA).
Responses were reported as the mean of triplicate samples
(mean [counts/minute cpm] ± standard deviation).
Enzyme-linked immunosorbent assay
Mature and active DCLCs were generated as described
above. Total IL-12 (p40 and p70) secreted by DCLCs primed
with pEGFP-IFIT4 or pEGFP-C1 transfection was measured
with the BIOSOURCE IL-12+p40 ELISA kit (Biosource
Europe S.A., Nivelles, Belgium) [45].
To examine the effect of IFIT4-primed DCLCs on T-cell polari-
zation, T cells (2 × 105/well) were plated and cultured with γ-
irradiated IFIT4-primed DCLCs at a ratio of DCLCs to T cells
of 1:10 for 6 days. 10 ng/ml of phorbol 12-myristate 13-ace-
tate (PMA) was added and the cells cultured for 1 more day.
The supernatants were harvested to measure the concentra-
tions of IL-4 and IFN-γ by using the Human IL-4/IFN-γ ELISA
Kit (Biosource Europe S.A.).
Statistical analysis
Two group comparisons of gene expression were assessed
using unpaired t-test, or the nonparametric Mann-Whitney test
when the data did not have a normal distribution [3,18,46,47].
Results are presented as the mean ± standard deviation
unless specified otherwise. Correlations of IFIT4 mRNA
expression levels with titre of auto-antibodies and SLE Dis-
ease Activity Index (SLEDAI) scores were determined using
Spearman's rank correlation coefficient [47].
Results
Increased expression of IFIT4 mRNA and protein in 
PBMCs and monocytes from SLE patients
A total of 108 SLE patients and 46 healthy donor individuals
were matched for both age and sex (Table 1). The results of
real-time quantitative RT-PCR revealed that the means of IFIT4
relative mRNA levels were 37.84 ± 3.52 in PBMCs from SLE
patients and 10.58 ± 2.64 in those from healthy control indi-
viduals, and the difference was statistically significant (P <
0.001; Figure 1a). IFIT4 protein levels, examined using West-
ern blotting, were significantly increased in PBMCs from 24
SLE patients than in those from the 24 healthy control individ-
uals (P < 0.05; Figure 1b,c). In addition, IFIT4 protein levels in
the monocytes of SLE patients were significantly increased
compared with those in control individuals (P < 0.05; Figure
1d).
Increased expression of IFIT4 is associated with 
autoantibodies in SLE
Spearman's correlation analysis was carried out to determine
the relationship between IFIT4 expression and the clinical
characteristics of SLE. We found that IFIT4 mRNA relative
expression correlated with ANA titre in 108 SLE patients (r =
0.4783, P < 0.001; Figure 2a), and with anti-dsDNA autoanti-
body titre in 36 SLE patients (r = 0.3932, P < 0.05; Figure
2b), and with anti-Sm antibody titre in seven SLE patients (r =
0.9088, P < 0.01; Figure 2c). Moreover, SLE patients who
were positive for anti-dsDNA autoantibodies had higher IFIT4
expression than did those who were negative (P = 0.0277;
Figure 2d). The difference in IFIT4 expression between
patients who were positive or negative for anti-Ro (anti-SSA;
Figure 2e) or anti-aCL/β2-GP1 (Figure 2f) was not statistically
significant (P > 0.05). Our findings suggest that higher IFIT4
expression is associated with a greater likelihood of having
autoantibodies against ribonucleoproteins.Page 4 of 12
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In the SLE population as a whole, we found that SLE patients
with hypocomplementaemia or leucopenia or/and thrombocy-
topenia usually had higher IFIT4 mRNA relative expression
than did SLE patients without these disorders (P = 0.0121,
Figure 2g; P = 0.0301, Figure 2h). However, IFIT4 expression
in PBMCs from SLE patients with or without nephritis was not
statistically different (P > 0.05; Figure 2i). We found no corre-
lation between IFIT4 gene expression and scores of the
SLEDAI-2K in 108 SLE patients (r = 0.0574, P > 0.05; Figure
2j).
IFIT4 protein is expressed predominantly in immune 
tissues and cells, and exclusively localized in the 
cytoplasm
IFIT4 was examined using real-time quantitative RT-PCR and
was found to be predominantly expressed in seven out of 14
normal human tissues, namely spleen, lung, leucocytes, lymph
nodes, placenta, bone marrow and foetal liver (in order of the
highest to the lowest), most of which belong to the immune
system (P < 0.05; Figure 3a). Rather than being restricted to
one immune cell, IFIT4 was expressed in many immune cells,
including CD19+, CD8+, CD14+ and CD4+ cells (P < 0.05;
Figure 3b).
To determine the the subcellular localization of IFIT4 protein,
THP-1 cells were transfected with pEGFP-C1 or pEGFP-IFIT4
plasmid and examined by confocal microscopy (Figure 3c). In
contrast to the pEGFP-C1 group, in which EGFP (enhanced
green fluorescent protein) was dispersed throughout the cell
(Figure 3c [subpanel a]), EGFP-IFIT4 fusion protein was spe-
cifically localized to the cytoplasm of THP-1 cells transfected
with pEGFP-IFIT4 (Figure 3 [subpanel b]), and no transloca-
tion of IFIT4 into the nucleus was observed after 3 days of
stimulation with IFN-α2a (Figure 3c [subpanel c]).
Strong induction of IFIT4 by IFN-α2a in vitro
IFIT4 mRNA and protein in normal PBMCs was preferentially
induced by IFN-α2a (3,000 units/ml), as observed using real-
time quantitative RT-PCR, fluorescence-activated cell sorting
(FACS), and Western blotting. The time course study revealed
strong induction of IFIT4 mRNA by IFN-α2a as early as 24
hours after treatment (Figure 3d). FACS findings showed that
IFIT4 protein was expressed in about 48.7% of normal
PBMCs, with mean fluorescence intensity of 121.18. How-
ever, after exposure to IFN-α2a for 3 days, up to 99.47%
PBMCs expressed IFIT4 protein with a mean fluorescence
intensity of 327.97 (P < 0.05; Figure 3e). Upregulation of
IFIT4 expression by IFN-α2a was confirmed by Western blot-
ting (Figure 3f).
Effect of IFIT4 on the morphological changes in the 
differentiation of monocytes into dendritic cells
Because it is usually difficult to transfect primary monocytes,
we chose an appropriate monocytic cell line, namely THP-1,
which has a suspended, rounded appearance and is widely
used as a model for monocyte-macrophage differentiation [42-
44,48,49]. We confirmed that THP-1 cells have the potential
to differentiate into mature DCLCs with various characteristics
of DC morphology (data not shown) after 12 days of treatment
with GM-CSF/IL-4 followed by stimulation with LPS for
another 2 days. An effect of IFIT4 on monocyte differentiation
into DCs in terms of morphological changes was observed.
Upon treatment with GM-CSF/IL-4 for 86 hours, no DC
Figure 1
Expression levels of IFIT4 in patients with SLE and healthy control indi-vidual
viduals. (a) Total RNA from the peripheral blood mononuclear cells 
(PBMCs) of 108 systemic lupus erythematosus (SLE) patients and 46 
healthy donor (HDs) was isolated, and the relative expression level of 
IFIT4 mRNA was determined by real-time quantitative RT-PCR. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was co-amplified as 
an internal control to normalize the amount of IFIT4 mRNA. All experi-
ments were repeated three times with similar results. Horizontal lines 
indicate the mean (P < 0.001, Mann-Whitney test). (b,c) Total protein 
was extracted from the PBMCs of 24 SLE patients and 24 HD control 
individuals. IFIT4 protein expression levels were detected using West-
ern blotting. β-Actin was used as a protein loading control. A set of ran-
dom data from eight SLE patients and eight HD controls is presented 
(P = 0.002, Mann-Whitney test). (d) Monocytes from three SLE 
patients and three HDs were isolated using magnetic beads. The IFIT4 
protein expression level in these monocytes was determined by West-
ern blotting. IFIT4, interferon-induced protein with tetratricopeptide 
repeats 4.Page 5 of 12
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Figure 2
Correlation analysis between IFIT4 expression and clinical assessments in SLE patients. Total RNA from the peripheral blood mononuclear cells 
(PBMCs) of 108 systemic lupus erythematosus (SLE) patients and 46 healthy donors (HDs) was isolated, and the relative expression levels of IFIT4 
mRNA were determined using real-time quantitative RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was coamplified as an internal 
control to normalize the amount of RNA. In the total SLE population, the relative expression of IFIT4 was plotted against the following: (a) the titre of 
antinuclear antibody (ANA) in a group of 108 SLE patients; (b) the titre of anti-double-stranded DNA antibody (anti-dsDNA) in 36 SLE patients; and 
(c) the titre of anti-Smith antibody (anti-Sm) in 7 SLE patients. Spearman's correlation test was used to analyze these data. In the SLE population as 
a whole, the relative expression of IFIT4 was determined using real-time quantitative RT-PCR in patients who were positive or negative for the follow-
ing: (d) anti-dsDNA antibody; (e) anti-SSA antibody; (f) anti-cardiolipid antibody or β-GP1 (ACL/b-GP1); (g) hypocomplementaemia (C3/C4 
decrease); (h) haematocytopenia (wbc/PLT decrease); and (i) lupus nephritis. Mann-Whitney test was used to analyze these data. (j) The relative 
expression of IFIT4 was plotted against Systemic Lupus Erythematosus Disease Activity Index-2,000 (SLEDAI-2000) and analyzed usingy Spear-
man's test. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.
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pEGFP-C1 vector (Figure 4a). Specifically, THP-1 cells
remained dispersed and rounded (left lane: ×20) and were
similar in size to intact THP-1 cells (right lane: ×40). In con-
trast, THP-1 cells primed with pEGFP-IFIT4 transfection par-
tially acquired DC morphology after as little as 48 hours of
GM-CSF/IL-4 treatment (Figure 4b). These IFIT4-primed
DCLCs not only aggregated into clusters and became half
adherent (left lane: ×20) but they also developed cytoplasmic
protrusions or dendrites around the cell surface and increased
in size (right lane: ×40). Moreover, THP-1 cells primed with
Figure 3
Distribution of IFIT4 in tissues and cells, and the effect of IFN-α on IFIT4 expression
IFIT4 expression. Using real-time quantitative RT-PCR, IFIT4 mRNA rel-
ative expression was determined among (a) 14 normal human tissues 
and (b) four kinds of immune cells. To determine the subcellular loca-
tion of IFIT4 protein, THP-1 cells were transfected with (c) (subpanel a) 
pEGFP-C1 control or (subpanel b) pEGFP-IFIT4 plasmid. Forty-eight 
hours later, cells were stained with DAPI for nuclear staining and exam-
ined by confocal microscopy. The effect of IFN-α2a on the localization 
of IFIT4 protein was also observed. (c) (subpanel c) THP-1 cells trans-
fected with pEGFP-IFIT4 were further stimulated with 3,000 μ/ml IFN-
α2a for 72 hours. Blue colour shows the location of the nucleus, 
whereas green colour shows the sublocalization of green fluorescent 
protein alone or fused with IFIT4 protein. (d) To analyze the effect of 
IFN-α on the expression level of IFIT4, peripheral blood mononuclear 
cells (PBMCs) from healthy donors were treated with 3,000 μ/ml IFN-
α2a for 24 hours, 48 hours or 72 hours, and then IFIT4 mRNA in the 
PBMCs was detected by real-time quatitative RT-PCR; all experiments 
were repeated three times with similar results. IFIT4 protein levels from 
normal PBMCs treated with IFN-α2a for 72 hours was examined by (e) 
flow cytometry with intracellular staining or (f) Western blotting with β-
actin as a protein loading control. The experiments were performed 
three times and a set of representative histograms and data is pre-
sented. IFIT4, interferon-induced protein with tetratricopeptide repeats 
4.
Figure 4
Morphological comparison of DCLCs primed with or without IFIT4 over-expression by inverted microscope
over-expression by inverted microscope. Cell morphology changes 
were observed to evaluate the effects of IFIT4 on dendritic cell (DC) 
differentiation upon treatment with granulocyte-macrophage colony-
stimulating factor (GM-CSF; 50 ng/ml) or IL-4 (20 ng/ml). (a) THP-1 
cells were transfected with pEGFP-C1; 36 hours later cells were fur-
ther stimulated with GM-CSF/IL-4 for 86 hours (left lane: ×20; right 
lane: ×40). (b) THP-1 cells were transfected with pEGFP-IFIT4 fusion 
plasmid; 36 hours later cells were further stimulated with GM-CSF/IL-4 
for 48 hours (left lane: ×20; right lane: ×40). (c) Effect of IFIT4 on mor-
phological changes that occured in monocytes differentiation into 
mature and activated DC-like cells (DCLCs). THP-1 cells were trans-
fected with pEGFP-IFIT4 (left lane) or pEGFP-C1 (right lane) plasmid; 
36 hours later cells were stimulated with GM-CSF/IL-4 for 6 days (left 
lane) or 12 days (right lane) followed by lipopolysaccharide (LPS; 100 
ng/ml) for another 2 days. All the cells above were observed with an 
inverted microscope. More than three fields of view (containing ≥100 
cells/field) per sample were examined. IFIT4, interferon-induced protein 
with tetratricopeptide repeats 4.Page 7 of 12
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for 6 to 8 days plus 2 days of LPS exhibited the distinct mature
and active morphology of DCs, manifesting as numerous proc-
esses and long veils, and dendrites (Figure 4c, left lane). How-
ever, 12 days of stimulation with GM-CSF/IL-4 was necessary
for THP-1 cells primed with pEGFP-C1 transfection to differ-
entiate into mature DCLCs (Figure 4c, right lane). These find-
ings indicate that IFIT4-primed DCLCs adapted DC
morphology sooner and had a greater resemblance to DCs
than did THP-1 transfected with control plasmid upon the
same GM-CSF/IL-4 treatment.
Effects of IFIT4 on increasing the expression of 
costimulatory molecules in DCLCs
We first assessed the expression background of related sur-
face markers of THP-1 cells by FACS. We found that CD14
was expressed at high levels, whereas CD80, CD86, CD1a
and CD1b were expressed at lower levels on the surface of
intact THP-1 cells (Figure 5a), confirming that THP-1 cells
were more consistent with a monocytic than a dendritic phe-
notype. To determine the effect of IFIT4 on DC differentiation
in terms of cell phenotypic changes, THP-1 cells primed with
pEGFP-C1 or pEGFP-IFIT4 transfection were treated with
GM-CSF/IL-4 for 90 hours; the cell surface markers were ana-
lyzed by flow cytometry. We found that DCLCs primed with
pEGFP-IFIT4 transfection expressed higher levels of CD40,
CD80, CD86 and HLA-DR, but lower levels of CD14 than did
those DCLCs primed with pEGFP-C1 transfection upon the
same GM-CSF/IL-4 stimulation (P < 0.05; Figure 5b). There
was no change in CD1a expression between the two groups
(Figure 5b).
Effect of IFIT4 in terms of enhancing the ability of DCLCs 
to present antigens to T cells
To examine further the effect of IFIT4 on modulating the ability
of DCLCs to activate T-cell proliferation, an allogeneic MLR
assay was conducted. Mature DCLCs primed with pEGFP-
IFIT4 or pEGFP-C1 were generated with 6 days of GM-CSF/
IL-4 stimulation and further treatment with 2 days of LPS, and
then these DCLCs were cultured with allogeneic CD4+ cells
with different ratios of DCLC to T cells. As shown in Figure 6a,
the extent of T-cell proliferation induced by DCLCs primed
with pEGFP-IFIT4 transfection was significantly higher than
those induced by DCLCs primed with pEGFP-C1, indicating
that IFIT4-primed DCLCs had a greater ability to induce T-cell
proliferation than controls (Figure 6a; P < 0.05).
Effect of IFIT4 on IL-12 secretion by activated DCLCs
To determine the effect of IFIT4 on IL-12 secretion by acti-
vated DCLCs, THP-1 cells transfected with pEGFP-IFIT4 or
pEGFP-C1 were stimulated with GM-CSF/IL-4 for 6 days and
further treated with LPS for 2 days (1 × 105 cells/ml) to gen-
erate mature, activated DCLCs. We found that the mature and
activated IFIT4-primed DCLCs produced more IL-12 than did
DCLCs primed with pEGFP-C1 transfection (Figure 6b; P <
0.05).
TH1 polarization by IFIT4-primed DCLCs
To address whether IFIT4 modulates the capacity of DCLCs
to direct T-helper cell differentiation, mature and activated
DCLCs were generated as described above. Then these
mature DCLCs were γ-irradiated followed by incubation with T
cells for 6 days. The ELISA findings revealed that T cells that
were stimulated with IFIT4-primed mature DCLCs secreted
more IFN-γ (about 2.4-fold) than did those stimulated with
DCLCs primed with pEGFP-C1 transfection (P < 0.05; Figure
6c). We did not find that any of the DCLCs affected IL-4
secretion to a significant degree (Figure 6c; P > 0.05).
Discussion
SLE is an autoimmune disease that is characterized by a break
in tolerance to nuclear components and by multi-tissue dam-
age. The pathogenesis of SLE has not been fully elucidated.
Increased expression of a spectrum of IFIGs in SLE [3,30-32],
the inherent responsiveness of these genes to Type I Inter-
feron (IFN-I) [29,30], and the correlation between IFN-I or
IFIGs and production of autoantibodies or disease severity
[18,50] indicate a coordinated activation of the IFN-I pathway
globally and a role for IFIGs in the pathogenesis of SLE [5,18].
In this study we found evidence that IFIT4, which was highly
expressed in patients with SLE, is associated with the pres-
ence of autoantibodies and hypocomplementaemia as well as
haematocytopenia. Most notably, IFIT4 might play a role in
monocyte differentiation into DCs, and hence contribute to the
mechanism by which autoantibodies become elevated and
some of the clinical manifestations present in SLE.
We confirmed that IFIT4 mRNA and protein were significantly
increased in PBMCs from SLE patients and positively corre-
lated with the presence of ANA, anti-dsDNA and anti-Sm/RNP
antinucleoprotein autoantibodies, which indicates that a role
of IFIT4 in the pathogenesis of SLE might be directly or indi-
rectly associated with the production of autoantibodies. SLE
patients with higher expression of IFIT4 exhibited a greater
prevalence of hypocomplementaemia, leucopenia and throm-
bocytopenia. The function of IFIT4 in antiproliferation [34]
might be partially responsible for the haematocytopenia
observed in patients with SLE, which requires further study in
the future. There was no apparent relationship between IFIT4
expression and the presence of renal disease or SLEDAI. The
clinical characteristics of IFIT4 are similar to those of another
IFIG, namely Mx1, whose expression is also positively associ-
ated with autoantibodies against SM/RNP and dsDNA, but
not with SLEDAI or the presence of renal disease [4]. IFN-α
score [18] was derived from many IFIGs (PRKR, IFIT1 and
IFI44) as measured by quantitative real-time PCR and repre-
sented the global activation of IFN-I pathway [3,18,29,30,51],.
We presumed that, unlike the IFN-α score, IFIT4 or Mx1, as
individual IFIG, was unable to be suggested to exclusivelyPage 8 of 12
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IFIT4 was found to be predominantly expressed in immune tis-
sues and cells, indicating a potential role for IFIT4 in immune
response. Both its extranuclear localization and its tetratr-
icopeptide repeat motifs provide some clues that emphasize
the role played by IFIT4 in the interaction between proteins via
its tetratricopeptide repeat domain. That no translocation into
nucleus took place after stimulation with IFN-α indicates that
Figure 5
Comparison of the phenotypic profiles of DCLCs primed with or without IFIT4 over-expression. (a) Surface antigens of normal THP-1 cells were 
examined by flow cytometry. (b) To analyze the effect of IFIT4 on phenotypic changes of dendritic cell-like cells (DCLCs) during the process of dif-
ferentiation, THP-1 cells were transfected with pEGFP-IFIT4 or pEGFP-C1; 36 hours later, cells were stimulated with granulocyte-macrophage col-
ony-stimulating factor (GM-CSF; 50 ng/ml) and IL-4 (20 ng/ml) for 90 hours to generate DCLCs. These DCLCs primed with pEGFP-IFIT4 or 
pEGFP-C1 transfection were incubated with fluorochrome-conjugated monoclonal antibodies (mAbs) and the antigens of CD40, CD80, CD86, 
CD83, HLA-DR, CD14 and CD1a on the surface of those DCLCs were analyzed by flow cytometry. Appropriate fluorochrome or isotype control 
mAbs of each antibody species were used as negative controls. Shaded histograms represent isotype control antibodies. The thick line represents 
DCLCs primed with pEGFP-IFIT4 transfection, whereas the slender lines represent DCLCs primed with pEGFP-C1 transfection. All experiments 
were performed three times and a set of representative histograms was presented. IFIT4, interferon-induced protein with tetratricopeptide repeats 4.Page 9 of 12
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information into the nucleus. IFIT4 was markedly induced by
IFN-α in normal PBMCs, indicating a role for IFIT4 as a down-
stream effector of IFN-α [28,29].
Both IFN-α [16,17,46] and IFIT4 were related to the presence
of autoantibodies. IFN-α might indirectly contribute to the gen-
eration of autoantibodies by inducing monocytes to differenti-
ate into DCs [2,41,52,53]. Our results showed that IFIT4
might be responsible for monocyte differentiation as a down-
stream effector of IFN-α. We found that the IFIT4-primed
DCLCs, in which IFIT4 was over-expressed, adopted DC mor-
phology sooner and exhibited a greater resemblance to DCs
than did DCLCs that were primed with control pEGFP-C1
transfection, in terms of becoming half adherent and develop-
ing dendrites (Figure 4). This indicates that IFIT4 promoted the
morphological changes that occurred during differentiation of
monocytes into DCs. Furthermore, compared with control
DLCLs, IFIT4-primed DCLCs exhibited a pattern of surface
markers that was more consistent with DCs, including greater
expression of the co-stimulatory molecules CD40, CD80,
CD86, HLA-DR and CD83, along with more obvious down-
regulation of the monocytic marker CD14 (Figure 5). Moreo-
ver, activated IFIT4-primed DCLCs induced stronger MLR and
produced more IL-12 than did control cells (Figure 6).
Collectively, these effects of IFIT4 on morphology, phenotype,
antigen-presenting ability and IL-12 production of monocytes
suggest that IFIT4 might play a role in promoting monocyte dif-
ferentiation into DCs. This is because IFIT4-primed cells
acquired more cytoplasmic protrusions or dendrites; more
expression of the co-stimulatory molecules CD40, CD80,
CD86, HLA-DR and CD83; lower expression of CD14;
stronger antigen-presenting ability; and more IL-12 produc-
tion. All of these are among the key characteristics of immature
or mature DCs. Moreover, IFIT4-primed DCLCs stimulated
greater IFN-γ secretion by T cells, which suggests that IFIT4
might direct DCs to modulate Th1 cell differentiation and
favour the ability of DCs to skew the immune response toward
Th1 development.
It was shown that monocytes from patients with SLE had
severely altered phenotype and lineage flexibility, and might
act as DCs [54,55]. For instance, they expressed significantly
lower levels of CD14 [54] and were able to induce strong
MLR [2], although HLA-DR levels were similar to [55] or lower
than [54,56] those of controls. The effect of IFIT4 on monocyte
differentiation into DCs was suggested to be partially respon-
sible for this unbalanced function of monocytes and DCs in
SLE [2]. The function of IFIT4 on differentiation and anti-prolif-
eration [34] indicated that IFIT4 might act as a regulator to bal-
ance proliferation and differentiation.
How might IFN-α and IFIT4 contribute to the pathogenesis of
SLE? Our hypothesis is that IFN-α and IFIT4 may act as 'adju-
Figure 6
Functional analysis of IFIT4-primed DCLCs. Mature and activated den-
dritic cell-like cells (DCLCs) were generated from THP-1 cells trans-
fected with pEGFP-IFIT4 or pEGFP-C1 and harvested after 6 days of 
culture with granulocyte-macrophage colony-stimulating factor (GM-
CSF)/IL-4 plus 2 days of stimulation with lipopolysaccharide (LPS; 100 
ng/ml). (a) Effect of IFIT4 on modulating the ability of DCLCs to 
present antigens to T cells was examined by allogeneic mixed leukocyte 
responses (MLRs). Allogeneic CD4+ T cells were cultured for 3 days 
with γ-irradiated mature DCLCs primed with pEGFP-C1 or pEGFP-
ITFIT4 transfection at different ratios of DCLCs to T cells (1:10, 1:20 
and 1:40). The cells were harvested and the incorporated radioactivity 
was measured using a beta counter. Responses are reported as the 
mean of triplicate samples (counts/minute [cpm] ± standard deviation). 
(b) Effect of IFIT4 on IL-12 production by DCLCs. Mature and activated 
DCLCs were generated as described above. Supernatant from the 
DCLCs (1 × 105 cells/ml) primed with pEGFP-C1 or pEGFP-ITFIT4 
transfection was analyzed for IL-12p70 by ELISA. (c) Analysis of the 
cytokine-production in T cells primed with co-stimulation by DCLCs. 
Mature and activated DCLCs primed with pEGFP-C1 or pEGFP-ITFIT4 
transfection were generated as described above. Then these mature 
and activated DCLCs were γ-irradiated and cultured with T cells at a 
ratio of DCLCs to T cells of 1:10 for 6 days. Phorbol-12-myristate-13-
acetate (PMA) (10 ng/ml) was added for another day. Finally, the cul-
ture medium was measured to assess IFN-γ and IL-4 produced by T 
cells by ELISA (T cells: 2 × 105 cells/ml; DCLC to T cell ratio = 1:10). 
DCLCs primed with pEGFP-IFIT4 (shaded histogram, test group) or 
pEGFP-C1 (open histogram, control group) were compared with each 
other. The results are expressed as the mean ± standard deviation. 
Data represent the mean of triplicate experiments. The asterisk indi-
cates a highly significant difference between the test group and the 
control (P < 0.05). IFIT4, interferon-induced protein with tetratricopep-
tide repeats 4.Page 10 of 12
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ignores self-antigens into an immune system that actively rec-
ognizes these antigens by promoting DC differentiation, matu-
ration and activation [21,57]. The activated DCs may present
ribonucleoprotein antigens in an immunogenic rather than
tolerogenic manner, leading to the activation of autoreactive T
cells that 'help' to drive autoantibody production in B cells
[58].
Conclusion
Our results indicate that IFIT4 might contribute to the patho-
genesis of SLE by inducing monocytes to differentiate into
DCs. This provides insight into the pathogenesis of SLE and
might lead to novel treatments [25,59].
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